The medical technology company Synthetic MR intends to carry out a fully secured rights issue of approximately SEK 32.8 million before issue costs. According to a press release.The terms are that each existing share on the record date entitles the holder to one subscription right, and two subscription rights entitle the holder to subscribe for one new share. The subscription price is SEK 1.10 per share. The subscription period runs between 20 January and 3 February next year.The dilution effect for shareholders who choose not to participate is approximately 33.3 percent of the company’s share capital and votes.The issue, which is conditional on approval at an extraordinary general meeting on 9 January, is intended primarily to finance the company’s commercial phase and continued development.The rights issue is secured to 100 percent through subscription undertakings from members of the board and management (with related parties), as well as through a subscription undertaking and a no-fee guarantee commitment from the company’s largest shareholder and board member, Staffan Persson, via Swedia Invest.